Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Earnings Presentation (May 2022)
17 slides from Sanofi Sa's earnings presentation, May 2022
Slide 1: Sanofi
sanofi
Slide 2: Accounting call
Accounting call Paris, May 2022
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts. These statements include projections and estimates and their underlyi
Slide 4: Contents
Contents 01 EUROAPI spin-off transaction accounting impact 02 Regeneron mAbs Alliance accounting Laurent Gilhodes Head of Group controlling & alliances Hervé Cardelli Head of consolidation and statutory reporting 4 Investor Relations
Slide 5: EUROAPI spin-off transaction accounting impact
EUROAPI spin-off transaction accounting impact
Slide 6: Transforming Sanofi to be focused and agile
Transforming Sanofi to be focused and agile Two year process to carve-out EUROAPI February 24th, 2020 January 18th, 2021 July 2021 Sanofi announced plans to EUROAPI CEO appointed: Viviane Monges joined create EUROAPI and Karl Rotthier EUROAPI as Chair of the initiated carve-out Supervisory Board Mar
Slide 7: EUROAPI spin-off
EUROAPI spin-off Global impact on SANOFI structure Deconsolidated from Sanofi accounts from May 10, 2022 IFRS 5 criteria met as of March 17, 2022 • EUROAPI assets and liabilities classified as EUROAPI 2021 historical sales €893m 1 “held for sale” in Q1.22 EUROAPI is not classified as a Discontinued
Slide 8: EUROAPI spin-off impact on Sanofi IFRS accounts
EUROAPI spin-off impact on Sanofi IFRS accounts Sanofi ceased consolidating EUROAPI on May 10th, 2022 (distribution settlement date). EUROAPI spin-off shares were measured: Total Net assets • based on stock market price on the settlement date for the distribution in kind (~58%) and the retained equi
Slide 9: EUROAPI deconsolidation impact on Sanofi Business P&L
EUROAPI deconsolidation impact on Sanofi Business P&L 2021 quarterly sales (General Medicines) + Positive impact on Gross Margin, mainly on Pharmaceuticals due to deconsolidation of Sales third-party sales impact of €486M in 2021 - EUROAPI mark-up on Sanofi purchase of API (Pharmaceuticals + CHC) €9
Slide 10: Regeneron mAbs Alliance Accounting
Regeneron mAbs Alliance Accounting
Slide 11: Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron
Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron1 Other operating income and expenses Worldwide sales from mAbs collaboration Regeneron commercial expenditure Consolidated by Sanofi Sanofi reimburses Regeneron for 100% of Regeneron’s Cost of sales commercial expenditu
Slide 12: Sanofi accounting of mAbs Alliance with Regeneron
Sanofi accounting of mAbs Alliance with Regeneron Other current operating income net of expenses € million H1 2021 H1 2020 2021 2020 Monoclonal Antibodies Alliance Income & Expense related to profit/loss sharing (521) (341) (1,253) (727) Additional share of profit paid by Regeneron related to develo
Slide 13: Q&A session
sonofi Q&A session
Slide 14: Appendix
Appendix
Slide 15: General Medicines 2021 sales
General Medicines 2021 sales Sales by Core and non-Core assets Sales in m€ 2021 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Lovenox 1486 335 383 367 401 Toujeo 969 230 239 247 253 Plavix 929 222 222 234 251 Multaq 329 99 79 79 72 Praluent 218 55 59 48 56 Thymoglobulin 350 87 91 92 80 Mozobil 233 63 60 58 52 Sol
Slide 16: Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron
Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron1 Last updated September 2021 US Ex-US Net sales Sanofi consolidates worldwide net sales Cost of sales Sanofi consolidates worldwide cost of sales R&D expense Development costs funded upfront by Sanofi until first positi
Slide 17: Sanofi Libtayo accounting pursuant to immuno-oncology License and Collaboration Agreement with Regeneron
Sanofi Libtayo® accounting pursuant to immuno-oncology License and Collaboration Agreement with Regeneron1,2 Last updated September 2021 US Ex-US Net sales Consolidated by Regeneron Consolidated by Sanofi Cost of sales Consolidated by Regeneron Consolidated by Sanofi R&D expenses Sanofi reimburses 5